Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Vaccinogen Inc -.--% -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+0.05%+3.08%+38.17%+66.77% 56.7B
+0.55%-5.98%+23.52%+62.15% 51.97B
+1.84%+1.27%-14.06%-13.50% 23.33B
-0.15%-6.00%-9.42%+344.47% 21.34B
+2.26%-1.00%+33.59%-25.37% 17.44B
+9.91%-2.51%+188.84%+326.19% 14.77B
+3.83%-1.34%+47.77%+165.22% 13.84B
+1.61%+0.56%+439.92%+166.12% 12.12B
+3.14%-12.56%+59.51%+149.39% 11.14B
Average +2.30%-2.33%+89.76%+137.94% 24.74B
Weighted average by Cap. +1.62%-1.95%+57.88%+109.55%
Logo Vaccinogen Inc
Vaccinogen, Inc. is a biotechnology company. The Company is the developer of OncoVAX. OncoVAX is an active specific immunotherapy (ASI) that uses the patient's own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. OncoVAX is a patient specific immunotherapy for stage II colon cancer and its technology may have application in other tumor types, such as melanoma and renal cell carcinoma. The OncoVAX patient-specific vaccine consists of sterile, metabolically active, irradiated and non-tumorigenic autologous cancer cells, with or without fresh frozen Bacillus Calmette-Guerin (BCG) bacteria as an adjuvant. The Company has completed a Phase IIIa study of OncoVAX.
Employees
-
  1. Stock Market
  2. Stocks
  3. VGEN Stock